---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-085446"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:19:39.223565+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kiniksa licenses vixarelimab to Genentech for $100M upfront; Q2 ARCALYST rev $27M

## Summary
- Genentech gets worldwide rights to vixarelimab; Kiniksa receives $100M upfront/near-term and up to $600M in milestones plus tiered royalties.
- ARCALYST Q2 2022 net revenue $27.0M (vs. $7.7M Q2 2021); full-year 2022 guidance reaffirmed at $115-130M.
- Q2 net loss narrowed to $20.0M (vs. $41.6M), with cash $138.2M and no debt; cash runway into 2025 after deal close.
- Phase 2b vixarelimab trial in prurigo nodularis screening complete; data disclosure delayed beyond H2 2022.
- Proceeds to fund cardiovascular pipeline expansion; ~20 additional ARCALYST sales reps planned in Q4 2022.

## SEC filing metadata
- accession: 0001104659-22-085446
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465922085446/0001104659-22-085446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465922085446/tm2222182d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-085446
- JSON: https://secwatch.observer/filing/0001104659-22-085446.json
- Plain text: https://secwatch.observer/filing/0001104659-22-085446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.